Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Vascular

No studies found 0 · 0%GRADE not reported 1 · 16.7%Very low 2 · 33.3%Low 2 · 33.3%Moderate 1 · 16.7%High 0 · 0%

Proximal DVT · people requiring prevention of venous thromboembolism

Fondaparinux showed no clear difference in proximal DVT compared with LMWH (low certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 0.58 [0.33, 1.02]
9 studies · 8361 participants
Low

Proximal DVT · people requiring prevention of venous thromboembolism

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 236 participants
Very low

Proximal DVT · people requiring prevention of venous thromboembolism

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 236 participants
Very low

Proximal DVT · people requiring prevention of venous thromboembolism

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
GRADE not reported

Proximal DVT · people requiring prevention of venous thromboembolism

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

Proximal DVT · people requiring prevention of venous thromboembolism

Fondaparinux probably leads to lower proximal DVT compared with placebo (moderate certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 0.12 [0.04, 0.39]
7 studies · 2746 participants
Moderate